ArticleFrontiers in bioengineering and biotechnology2026
Human umbilical cord-derived mesenchymal stem cells/Bio-Oss granules composite prevents medication-related osteonecrosis of the jaw in a rat model.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the preventive efficacy of human umbilical cord-derived mesenchymal stem cells (hucMSCs)/Bio-Oss granules composite in a rat model of medication-related osteonecrosis of the jaw (MRONJ). Materials and methods: Twenty-four rats were randomly allocated into a negative control group, a model control group, a Bio-Oss granules group, and a composite group (n = 6). All groups except the negative control group received intraperitoneal injections of zoledronic acid (0.1 mg/kg) 3 times per week for 12 weeks to induce MRONJ-like lesions. After 4 weeks of drug administration, standardized bone defects were prepared at the mandibular molar extraction sites. In the negative control and model control groups, the defects were left unfilled. In the Bio-Oss granules and composite groups, the defects were filled with Bio-Oss granules or hucMSCs/Bio-Oss granules composite, respectively. All rats were euthanized 8 weeks after surgery. Macroscopic observation, micro-CT evaluation, and histological analysis were conducted to assess bone exposure rate, bone volume fraction (BV/TV), bone mineral density (BMD), and the percentage of empty osteocyte lacunae. Results: The bone exposure rate was 0% in both the negative control and composite groups, compared with 83.33% and 66.67% in the model control and Bio-Oss granules groups, respectively. The composite group showed improved mucosal coverage, as well as significantly higher BV/TV and BMD and fewer empty osteocyte lacunae than the other bisphosphonate (BP)-treated groups ( Conclusion: Bio-Oss granules alone showed limited efficacy in preventing MRONJ. In contrast, the hucMSCs/Bio-Oss granules composite effectively promoted mucosal healing and bone regeneration, thereby preventing the development of MRONJ in BP-treated rats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.